mactel cntf - SERP Analysis

https://www.fightingblindness.org/news/neurotech-s-encapsulated-cell-technology-receives-fda-approval-for-treatment-of-mactel-1960

https://pmc.ncbi.nlm.nih.gov/articles/PMC4361328/

https://www.lmri.net/phase3-enrolling/

https://www.neurotechpharmaceuticals.com/clinical-trials/

https://www.retinalphysician.com/issues/2024/june/macular-telangiectasia-new-hope-on-the-horizon/

https://www.aaojournal.org/cms/10.1016/j.ophtha.2018.09.041/attachment/076ec556-d4e1-4071-9789-15c31dae9dd7/mmc4.pdf

https://www.escrs.org/channels/eurotimes-articles/neuroprotectant-treatment-for-mactel-type-2

https://iovs.arvojournals.org/article.aspx?articleid=2788292

https://www.ophthalmologytimes.com/view/neurotech-pharmaceuticals-receives-priority-review-of-bla-for-nt-501-for-treatment-of-mactel

https://www.primetherapeutics.com/high-cost-therapy-profile-february-2025

https://www.empr.com/news/fda-extends-review-of-cntf-ocular-implant-for-macular-telangiectasia/

https://pmc.ncbi.nlm.nih.gov/articles/PMC5700868/

https://www.retinalphysician.com/issues/2024/october/pooled-visual-function-data-of-nt-501/

https://www.businesswire.com/news/home/20241106194221/en/Neurotech-Provides-Update-on-BLA-for-NT-501-as-a-Treatment-for-Macular-Telangiectasia-Type-2-MacTel

https://www.aao.org/eyenet/academy-live/detail/phase-2-cntf-trial-shows-promise-in-people-with-ma

https://www.lmri.net/nov2024-bla-update/

https://www.ophthalmologytimes.com/view/fda-approves-revakinagene-taroretcel-lwey-encelto-for-macular-telangiectasia-type-2

https://iovs.arvojournals.org/article.aspx?articleid=2331546

https://www.bioworld.com/articles/718087-neurotechs-cntf-implant-approved-for-macular-telangiectasia

https://www.researchgate.net/publication/269934989_Ciliary_Neurotrophic_Factor_CNTF_for_Macular_Telangiectasia_Type_2_MacTel_Results_from_a_phase_I_safety_trial

https://www.medpagetoday.com/meetingcoverage/aao/107231

https://www.cgtlive.com/view/neurotech-encapsulated-cell-therapy-encelto-approved-fda-macular-telangiectasia-type-2

https://eyewire.news/news/neurotech-receives-priority-review-of-biologics-license-application-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2-mactel

https://grantome.com/grant/NIH/ZIA-EY000536-05

https://umiamihealth.org/en/clinical-trials/safety-study-to-evaluate-bilateral-cntf-implants-in-subjects-with-mactel-type-2

https://www.hcplive.com/view/roger-a-goldberg-md-pooled-visual-function-data-nt-501-mactel

https://ctv.veeva.com/study/a-study-to-determine-the-safety-and-efficacy-of-nt-501-with-mhfm

https://www.neurotechpharmaceuticals.com/wp-content/uploads/Neurotech_Press-Release_BLA_FINAL-1.pdf

https://horizonscandb.pcori.org/report/topics/174

https://med.emory.edu/departments/ophthalmology/about/news-eec/2022/3-mactel.html

https://www.macularsociety.org/macular-disease/macular-conditions/mac-tel/

https://cdek.pharmacy.purdue.edu/trial/NCT06397131/

https://www.modernretina.com/view/aao-2024-an-update-from-neurotech-on-mactel-treatment-candidate

https://www.sciencedirect.com/science/article/abs/pii/S0002939414008198

https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/mactel-type-2_-ntmt-03-phase-3-trial/

https://glance.eyesoneyecare.com/stories/2024-06-24/neurotech-pharma-earns-bla-priority-review-for-mactel-cell-therapy/

https://www.retina-specialist.com/article/trial-updates-in-ga-mactel-type-2-and-dme

https://www.asgct.org/Publications/News/March-2025/Encelto-Cell-Therapy-Degenerative-Eye-Disease

https://www.scripps.edu/news-and-events/press-room/2025/20250604-friedlander-encelnto.html

https://www.aaojournal.org/article/S0161-6420(18)31427-1/abstract

https://eyewiki.org/Macular_Telangiectasia

https://www.aao.org/education/headline/novel-implant-macular-telangiectasia-gains-fast-tr

https://www.ophthalmologyadvisor.com/reports/revakinagene-taroretcel-reduces-progression-of-macular-telangiectasia-type-2/

https://retinaroundup.com/2023/11/06/aao-2023-charles-l-schepens-lecture-with-dr-emily-chew/

https://lowvision.preventblindness.org/new-drug-approved-for-treatment-of-macular-telangiectasia-type-2-mactel/

https://www.neuro-central.com/neurotech-pharmaceuticals-inc-announces-positive-phase-3-topline-results-for-nt-501-implant-in-macular-telangiectasia-type-2/

https://www.modernretina.com/view/the-fda-extends-the-pdufa-for-the-biologics-license-application-of-nt-501

https://www.linkedin.com/posts/retina-global_encelto-mactel-cntf-activity-7303840380909670400-9H0T

https://www.nature.com/articles/s41467-022-34443-x

https://fluorescene.odcommunity.com/mactel-a-case-of-mistaken-identity/

https://eyeonoptics.com.au/live-articles/fda-approves-macular-telangiectasia-therapy/

https://miislibrarysearch.middlebury.edu/discovery/fulldisplay?docid=cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4361328&context=PC&vid=01MIDDLE_INST:01MIDDLE_INST_cm&lang=en&search_scope=MIISCAMPUS&adaptor=Primo%20Central&tab=Campus&query=creator%2Cequals%2C%20Tao%2C%20Weng%2CAND&mode=advanced&offset=10

https://fdaaa.trialstracker.net/sponsor/neurotech-pharmaceuticals/

https://www.delveinsight.com/blog/encelto-for-mactel

https://www.ajmc.com/view/revakinagene-taroretcel-approval-addresses-unmet-need-in-mactel

https://theophthalmologist.com/subspecialties/a-tiny-factory

https://www.rxlist.com/ciliary_neurotrophic_factor_cntf/drug-class.htm

https://www.ophth.wisc.edu/blog/2017/02/14/ntmt/

https://www.ddw-online.com/fda-approves-first-treatment-for-macular-telangiectasia-type-2-33938-202503/

https://www.sciencedirect.com/science/article/pii/S1043661824001038?dgcid=rss_sd_all

https://www.academia.edu/13882516/Ciliary_Neurotrophic_Factor_for_Macular_Telangiectasia_Type_2_Results_From_a_Phase_1_Safety_Trial

https://experts.umich.edu/1513-grant-comer/grants

https://www.claritasrx.com/blog/fda-approval-encelto/

https://www.reviewofophthalmology.com/article/update-on-macular-telangiectasia-type2-mactel

https://www.retina-specialist.com/article/gaining-new-insights-into-mactel

https://www.optometrytimes.com/view/fda-grants-priority-review-to-novel-treatment-for-macular-telangiectasia-type-2

https://www.houstonmethodist.org/leading-medicine-blog/articles/2025/may/fda-approves-first-treatment-for-macular-telangiectasia-type-2-with-houston-methodist-among-top/

https://www.dovepress.com/macular-telangiectasia-type-2-a-comprehensive-review-peer-reviewed-fulltext-article-OPTH

https://synapse.patsnap.com/organization/0d0b957ed80eb57d395ff6444e100a78

https://www.lei.org.au/research/clinical-trials/ntmt-01-02e-neurotech-pharmaceutics-inc-lowy-medical-research-institute/

https://www.biospace.com/press-releases/neurotechs-encelto-revakinagene-taroretcel-lwey-approved-by-the-fda-for-the-treatment-of-macular-telangiectasia-type-2-mactel

https://vitbucklesociety.org/2019/10/29/effect-of-ciliary-neurotrophic-factor-on-retinal-neurodegeneration-in-patients-with-macular-telangiectasia-type-2/

https://journals.lww.com/retinajournal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00006982-201801001-00006

https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-023-00505-5

https://glance.eyesoneyecare.com/press-releases/neurotech-pharmaceuticals-inc-receives-priority-review-of-biologics-license-application-for-nt-501-revakinagene-taroretcel-as-treatment-for-mactel/

https://piemagazine.org/neurotechs-nt-501-bla-for-mactel-treatment-delayed-for-additional-fda-review/

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2723642

https://www.researchgate.net/publication/328085880_Effect_of_Ciliary_Neurotrophic_Factor_on_Retinal_Neurodegeneration_in_Patients_with_Macular_Telangiectasia_Type_2_A_Randomized_Clinical_Trial

https://www.em-consulte.com/article/961349/ciliary-neurotrophic-factor-for-macular-telangiect

https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003234-82/FR

https://www.drugs.com/newdrugs/fda-approves-encelto-revakinagene-taroretcel-lwey-macular-telangiectasia-type-2-mactel-6471.html

https://www.cgtlive.com/view/nt-501-cell-therapy-slows-degeneration-macular-telangiectasia

https://www.ophth.wisc.edu/blog/2020/12/01/mac-tel/

https://journalofmedicaloptometry.com/volume2-issue1/diagnosing-macular-telangiectasia-type-2/

https://trial.medpath.com/news/b4e8dac39fd76ab8/phase-3-trial-shows-promising-results-for-novel-encapsulated-cell-therapy-in-mactel-treatment

https://link.springer.com/article/10.1007/s40123-019-0170-1

https://pdfs.semanticscholar.org/5e95/c1bc0207e03877163fca29f37d1e83f40de6.pdf

https://diseases.jensenlab.org/Entity?documents=10&type1=9606&id1=ENSP00000355370&type2=-26&id2=DOID:1272

https://www.ajmc.com/view/fda-approves-revakinagene-taroretcel-for-macular-telangiectasia-type-2

https://en.wikipedia.org/wiki/Macular_telangiectasia

https://journals.viamedica.pl/ophthalmology_journal/article/download/OJ.2017.0018/42801

https://synapse.patsnap.com/blog/neurotech-pharmaceuticals-nt-501-revakinagene-taroretcel-bla-for-macular-telangiectasia-type-2-gets-priority-review

https://www.retina-doctors.com/research-trials/clinical-trials/list-of-clinical-trials

https://entokey.com/ciliary-neurotrophic-factor-for-macular-telangiectasia-type-2-results-from-a-phase-1-safety-trial/

https://www.youtube.com/watch?v=0BcYkSbVlXo

https://retinaroundup.com/2023/08/02/asrs-2023-late-breaking-abstracts-for-wet-amd-dme-and-mactel/

https://x.com/JavierGC280/status/1902243852771053691

https://ctv.veeva.com/study/a-study-to-determine-the-safety-and-efficacy-of-nt-501-in-macular-telangiectasia-type2

https://www.facebook.com/TheMacularTelangiectasiaGroup/posts/what-a-great-read-we-hope-some-of-the-mactel-project-researchers-who-follow-our-/1354371418005038/